Pharmaceutical News

RSS

WHO issues new guidelines for malaria treatment

The World Health Organization (WHO) is releasing new guidelines for the treatment of malaria, and the first ever guidance on procuring safe and efficacious anti-malarial medicines.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

Watson Pharmaceuticals resolves Actos patent litigation

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

11 Mar 2010

Forteo therapy may speed healing, improve patient outcomes after rotator cuff surgery

Tears in the shoulder's rotator cuff, a common sports injury, are painful and restricting. Surgery to repair the damage is successful for pain management, but in many patients it does not result in full recovery of function due to poor healing. New research shows an approved therapy for osteoporosis, Forteo, may speed healing and improve patient outcomes.

11 Mar 2010

Comparative research lags far behind approval-driven evaluations

A new study has found that few drug evaluations compare treatments in ways that help doctors make better decisions, Reuters reports.

11 Mar 2010

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Cannabis Science, Inc., a pioneering pharmaceutical cannabis company, is pleased to announce that it has formalized its agreement with a privately owned, highly specialized international FDA regulatory compliance firm. The compliance firm will review and prepare technical data for Cannabis Science's FDA Pre-Investigative New Drug submission package for its Veterans PTSD Project.

11 Mar 2010

Majority of nurse practitioners recommend dietary supplements for overall health and wellness

Eighty-five percent of nurse practitioners agree that one of the roles of healthcare professionals is to provide their patients with information about dietary supplements, according to new research from the "Life...supplemented" 2009 Healthcare Professionals (HCP) Impact Study.

11 Mar 2010

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation’s largest pharmacy chains with 7,162 drugstores located throughout the United States.

11 Mar 2010

Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity

Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.

11 Mar 2010

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.

11 Mar 2010

FDA sponsoring workshops to increase rare disease treatment options

The Wall Street Journal: FDA is putting on workshops for pharmaceutical manufacturers to increase the pool of applicants for approved "orphan drugs," that treat rare diseases. Currently, there are about 7,000 so-called orphan diseases in the U.S. that have few or no FDA-approved treatments.

11 Mar 2010

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.

11 Mar 2010

Clinical trial shows eprotirome drug reduces blood cholesterol

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

11 Mar 2010

GSK to offer flexible drug pricing in middle-income countries

Drug maker GlaxoSmithKline (GSK) "plans to bolster earnings by selling to more people in middle-income countries after cutting prices in the world's poorest nations," Bloomberg/BusinessWeek reports.

11 Mar 2010

Polio immunization campaign begins across West and Central Africa

More than 85 million children under five years old will be immunized against polio in 19 countries across West and Central Africa in a massive example of cross-border cooperation aimed at stopping a year-long polio epidemic.

10 Mar 2010

Small study shows eprotirome decreases LDL cholesterol

People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

10 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

Eprotirome lowers bad cholesterol, triglycerides and Lp(A) without statin side effects

A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.

10 Mar 2010

FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel

Oculus Innovative Sciences, Inc., a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel.

10 Mar 2010

$Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures$

Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

10 Mar 2010

Pharmaceutical News

WHO issues new guidelines for malaria treatment

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Watson Pharmaceuticals resolves Actos patent litigation

Forteo therapy may speed healing, improve patient outcomes after rotator cuff surgery

Comparative research lags far behind approval-driven evaluations

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Majority of nurse practitioners recommend dietary supplements for overall health and wellness

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

FDA sponsoring workshops to increase rare disease treatment options

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Clinical trial shows eprotirome drug reduces blood cholesterol

GSK to offer flexible drug pricing in middle-income countries

Polio immunization campaign begins across West and Central Africa

Small study shows eprotirome decreases LDL cholesterol

DSPA's lurasidone NDA accepted for FDA review

Eprotirome lowers bad cholesterol, triglycerides and Lp(A) without statin side effects

FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel

Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News